The Application of Transcutaneous CO2 Partial Pressure Monitoring in the Anesthesia of Patients Undergoing Retroperitoneoscopic Urologic Surgery

The First Affiliated Hospital with Nanjing Medical University1 site in 1 country32 target enrollmentJuly 20, 2017

ConditionsTranscutaneous Carbon Dioxide Partial Pressure Monitoring Retroperitoneoscopic Urologic Surgery

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Transcutaneous Carbon Dioxide Partial Pressure Monitoring
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Enrollment: 32
Locations: 1
Primary Endpoint: Bias and precision of the transcutaneous carbon dioxide measurements
Status: Completed
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

To investigate the accuracy and correlation of estimating arterial CO2 pressure（PaCO2） using a transcutaneous CO2 pressure（PTCCO2） monitor in patients undergoing retroperitoneoscopic renal or adrenal surgery.

Detailed Description

30 patients undergoing retroperitoneoscopic renal or adrenal surgery were included in this study.Their PaCO2, PetCO2, and PTCCO2values were measured at 3 time points before and 30min, 60min after pneumoperitoneum and calculated the different between each measure(PetCO2 and PTCCO2) and PaCO2. Agreement among measures was assessed by the Bland-Altman method.

Registry

clinicaltrials.gov

Start Date

July 20, 2017

End Date

June 30, 2020

Last Updated

5 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•patients undergoing retroperitoneoscopic renal or adrenal surgery
•Age more than 16 years.

Exclusion Criteria

•Care taker unable or unwilling to give oral informed consent
•Patients with history of severe trauma, operations, smoking, and severe cardiovascular or respiratory diseases, such as coronary heart disease, congestive heart failure, or chronic obstructive pulmonary disease
•4.Subject has a condition or allergy which would prohibit placing the probe 5.Subject has participated in a trial with any experimental drug or device trial within 30 days prior to enrollment in the study

Outcomes

Primary Outcomes

Bias and precision of the transcutaneous carbon dioxide measurements

Time Frame: 60 minutes

correlation and agreement between PetCO2 and PaCO2 and PTCCO2

Secondary Outcomes

complication: appearance of signs of thermal injury (redness, skin erythema, blisters, necrosis) under application of transcutaneous sensor temperatures of 44°C )(60 minutes)